Welcome to our dedicated page for Ikena Oncology news (Ticker: IKNA), a resource for investors and traders seeking the latest updates and insights on Ikena Oncology stock.
This page provides a historical news archive for Ikena Oncology, Inc., which traded on Nasdaq under the symbol IKNA before its merger with Inmagene Biopharmaceuticals and subsequent name change to neBio, Inc. The articles collected here trace how Ikena evolved from a targeted oncology company into part of a broader clinical-stage biotechnology organization whose stock now trades under the ticker IMA.
Earlier news under IKNA focuses on Ikena’s targeted oncology programs, including IK-930, a TEAD1-selective Hippo pathway inhibitor, and IK-595, a MEK-RAF molecular glue studied in patients with RAS and RAF mutant cancers. Releases detail clinical progress such as Phase 1 dose escalation, pharmacokinetics and pharmacodynamics observations, and strategic decisions like the discontinuation of IK-930 and workforce restructuring. Financial updates outline Ikena’s cash position, research and development spending, and its evaluation of strategic options for the company and its pipeline.
Subsequent news documents the agreement and completion of a merger with Inmagene Biopharmaceuticals, the approval of the transaction by Ikena stockholders, and the implementation of a 1-for-12 reverse stock split. Coverage explains that the combined company would operate as neBio, Inc., focus on developing -007, a non-depleting anti-OX40 monoclonal antibody for immunological and inflammatory diseases, and trade on Nasdaq under the symbol IMA. Additional items describe the establishment of contingent value rights for Ikena’s legacy assets and governance and compensation plans for the combined company.
Investors and researchers can use this IKNA news archive to follow the sequence of clinical, financial, and corporate events that led from Ikena’s oncology-focused operations to its transformation into neBio, Inc. and the shift in emphasis toward immunological and inflammatory disease programs centered on -007.
Ikena Oncology (Nasdaq: IKNA) will participate in the William Blair Biotech Focus Conference on July 15, 2021. CEO Dr. Mark Manfredi will engage in a panel discussion focused on next-generation approaches to targeted oncology. The panel is scheduled for 9:00 – 9:45 a.m. ET and will be available via a live webcast. Ikena is known for developing therapies targeting cancer's key signaling pathways and has ongoing programs including IK-930 and IK-175. The webcast will be archived for 30 days after the event.
Ikena Oncology (Nasdaq: IKNA) will participate in a fireside chat at the 2021 Jefferies Virtual Healthcare Conference on June 2, 2021, at 2:00 p.m. ET. The event will be available through a live webcast on the company's website, with an archive accessible for 30 days post-event. Ikena is focused on cancer therapies targeting key signaling pathways and has five active programs, including collaborations with Bristol-Myers Squibb for IK-175 and IK-412. For more details, visit www.ikenaoncology.com.
Ikena Oncology (Nasdaq: IKNA) reported its financial results for Q1 2021, marking significant milestones including a successful IPO that raised $143.8 million. The company is focused on developing targeted cancer therapies and has made progress with its clinical pipeline. IND-enabling studies for lead program IK-930 are ongoing, with a submission expected in H2 2021. As of March 31, 2021, Ikena had $281 million in cash, with a net loss of $9.7 million for the quarter, driven by increased R&D expenses.
Ikena Oncology, Inc. (Nasdaq: IKNA) has appointed Maria Koehler, M.D., Ph.D., to its Board of Directors. Dr. Koehler has over 20 years of experience in oncology drug development, previously holding senior positions at Pfizer and leading the development of Ibrance®. Mark Manfredi, CEO of Ikena, expressed enthusiasm for her addition during the company's growth phase, especially as it advances its lead candidate IK-930 into clinical development. Dr. Koehler aims to leverage her extensive experience to drive Ikena's innovative drug candidates forward.
Ikena Oncology, Inc. (Nasdaq: IKNA) announced the closure of its initial public offering (IPO) on 8,984,375 shares of common stock at a price of $16.00 per share, raising approximately $143.8 million in gross proceeds. The offering included the full exercise of the underwriters' option for an additional 1,171,875 shares. Jefferies, Cowen, Credit Suisse, and William Blair served as joint book-running managers. Ikena focuses on cancer therapies targeting critical signaling pathways and has five development programs, including collaborations with Bristol-Myers Squibb.
Ikena Oncology announced the pricing of its initial public offering (IPO), offering 7,812,500 shares at $16.00 each, aimed to raise gross proceeds of $125.0 million. The shares will trade on the Nasdaq starting March 26, 2021, under the ticker symbol IKNA, with the offering expected to close on March 30, 2021. A 30-day option has been granted to underwriters for an additional 1,171,875 shares. Ikena focuses on developing cancer therapies targeting key signaling pathways, and has five programs in development, including collaborations with Bristol-Myers Squibb.